Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for REQUIP XL
- Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
- Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis
- Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fasting Conditions
- Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fed Conditions
- Two Way Cross Over BE Fasting Pilot Study of Ropinirole Hydrochloride CR 2mg Tablets
- Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition
- Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition
- Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528
- Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)
- Cognitive Remediation for Cocaine Dependence
- A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda
- REQUIP RLS Post Marketing Surveillance
- A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa
- The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions
- Ropinirole 0.25 mg Tablets Under Fasting Conditions
- A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions
- A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
- Neuroma Injections to Treat Restless Legs Syndrome - RCT
- Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type
- An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
- MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
- REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study
- A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
- Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
- SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole
- Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo
- A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's
- Ropinirole in the Treatment of Bipolar Depression
- Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease
- Pramipexole Conversion to Ropinirole Controlled Release (CR)
- Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease
- Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
- Talampanel to Treat Parkinson's Disease
- ACP-103 to Treat Parkinson's Disease
- Levetiracetam Treatment of L-dopa Induced Dyskinesias
- JP-1730 to Treat Parkinson's Disease
Clinical trials list
click for details